CIViC Evidence Items

28 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
B	IDH1	R132	Prognostic	Supports	Better Outcome	Glioblastoma		Yan et al., 2009
B	IDH1	R132	Prognostic	Supports	Better Outcome	Malignant Astrocytoma		Yan et al., 2009
A	IDH1	R132	Predictive	Supports	Sensitivity/Response	Cholangiocarcinoma	Ivosidenib	Abou-Alfa et al., 2020
A	IDH1	R132C OR IDH1 R132H OR IDH1 R132L OR IDH1 R132G OR IDH1 R132S	Predictive	Supports	Sensitivity/Response	Low Grade Glioma	Vorasidenib	Mellinghoff et al., 2023
B	IDH1	R132	Prognostic	Supports	Poor Outcome	Myelodysplastic Syndrome		Thol et al., 2010
D	IDH1	R132H	Predictive	Supports	Sensitivity/Response	Oligodendroglioma	AGI-5198	Rohle et al., 2013
D	IDH1	R132	Predictive	Supports	Sensitivity/Response	Intrahepatic Cholangiocarcinoma	Dasatinib	Saha et al., 2016
B	IDH1	Mutation	Prognostic	Supports	Better Outcome	Chondrosarcoma		Zhu et al., 2020
B	IDH1	R132	Prognostic	Does Not Support		Acute Myeloid Leukemia		Schnittger et al., 2010
B	IDH1	R132C	Diagnostic	Supports	Positive	Acute Myeloid Leukemia		Abbas et al., 2010
B	IDH1	R132	Prognostic	Supports	Better Outcome	Malignant Astrocytoma		Dubbink et al., 2009
B	IDH1	R132	Prognostic	Supports	Better Outcome	Glioblastoma		Bleeker et al., 2010
D	IDH1	R132C	Predictive	Supports	Sensitivity/Response	Acute Myeloid Leukemia	GSK321	Okoye-Okafor et al., 2015
B	IDH1	Mutation	Prognostic	Supports	Better Outcome	Brain Glioma		2015, N. Engl. J. Med.
D	IDH1	R132C	Predictive	Supports	Sensitivity/Response	Acute Myeloid Leukemia	BPTES	Emadi et al., 2014
D	IDH1	Mutation	Predictive	Supports	Sensitivity/Response	Brain Glioma	Olaparib	Sulkowski et al., 2017
A	IDH1	Mutation	Predictive	Supports	Sensitivity/Response	Acute Myeloid Leukemia	Ivosidenib	DiNardo et al., 2018
B	IDH1	Mutation	Predictive	Supports	Sensitivity/Response	Cholangiocarcinoma	Ivosidenib	Lowery et al., 2019
C	IDH1	Mutation	Predictive	Supports	Sensitivity/Response	Acute Myeloid Leukemia	Venetoclax	Huemer et al., 2019
D	IDH1	R132C	Predictive	Supports	Sensitivity/Response	Cancer	Olaparib	Sulkowski et al., 2017
B	IDH1	R132	Diagnostic	Supports	Positive	Acute Myeloid Leukemia		Ho et al., 2010
B	IDH1	R132	Prognostic	Does Not Support		Acute Myeloid Leukemia		Wagner et al., 2010
B	IDH1	R132C	Prognostic	Does Not Support		Acute Myeloid Leukemia		Abbas et al., 2010
B	IDH1	R132	Predictive	Supports	Sensitivity/Response	High Grade Glioma	Sunitinib,Bevacizumab	Lv et al., 2011
B	IDH1	R132C	Predictive	Supports	Sensitivity/Response	Brain Glioma	Temozolomide	Houillier et al., 2010
D	IDH1	R132C	Predictive	Supports	Sensitivity/Response	High Grade Glioma	AGI-5198	Rohle et al., 2013
B	IDH1	R132C	Predictive	Supports	Sensitivity/Response	Acute Myeloid Leukemia	Ivosidenib	2015
C	IDH1	R132H	Predictive	Does Not Support	Sensitivity/Response	Pancreatic Ductal Adenocarcinoma	Ivosidenib	Brody et al., 2018